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Abstract
Patients with hematological malignancies and recipients of allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT) as well as solid organ transplant recipients 
are the groups of patients with the highest risk of invasive fungal infections (IFI). 
Neutropenia, lymphopenia, chemotherapy of malignancies, radiation therapy, 
immunosuppressive therapy, administration of glucocorticosteroids, use of central 
venous catheters, dialysis therapy, liver and kidney failure, and diabetes are diseases 
and medical conditions which foster invasive fungal infections. In recent years, it has 
been observed that the most common etiological agents of these infections are yeast-
like fungi of the genus Candida, and the second most common is moulds Aspergillus 
spp. Antifungal agent recommended for therapy of IFI caused by Aspergillus is vori-
conazole, according to the present guidelines. A combined therapy using voriconazole 
and caspofungin may not be effective. According to numerous publications, in case of 
infections caused by strains resistant to voriconazole, a therapeutic success is possible 
after a switch to the liposomal form of amphotericin B. Due to nonspecific clinical 
symptoms of IFI caused by Aspergillus spp., histopathological as well as mycological 
and serological tests, echocardiographic examination, magnetic resonance imag-
ing (MRI) and computer tomography (CT) may contribute to an early and reliable 
diagnosis of invasive aspergillosis.
Keywords: Aspergillus fumigatus, invasive fungal infection, risk factors,  
antifungal therapy
1. Introduction
Transplant recipients constitute a group of patients who are immunocompromised. 
Among them, hematopoietic stem cell transplant (HSCT) recipients suffer from the 
most severe immunosuppression, which may be prolonged. Many risk factors make 
these patients prone to fungal infections caused by yeast-like fungi or molds.
Filamentous fungi of the genus Aspergillus may cause many clinical forms of 
the disease in immunocompromised patients (including HSCT recipients and solid 
organ transplant recipients), but increasingly also in patients undergoing intensive 
care or even without any immune deficiencies [1]. Aspergillosis usually results from 
inhalation of spores, affecting primarily the respiratory system [1–3]. Humans 
are exposed daily to massive numbers of fungal spores; however, usually they are 
eliminated by various pulmonary defense mechanisms, for example, mucocili-
ary function [1, 2]. With progress in molecular diagnostic methods, particularly 
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next-generation sequencing (NGS) techniques, we have learned that molds and 
yeast-like fungi are present in the respiratory tract, even in healthy individuals 
[4]. Similar to microbiota composition in other parts of the body, the lung myco-
biota also comprises numerous fungal species, which become less diverse in many 
diseases [4].
Aspergillosis may present in different forms, such as invasive aspergillosis (IA), 
allergic aspergillosis, chronic pulmonary aspergillosis, and as superficial disease 
in various anatomical locations (keratitis, otomycosis, and wound infections) [1, 
4–6]. Allergic aspergillosis may present as allergic bronchopulmonary aspergillosis 
(ABPA) and allergic fungal rhinosinusitis (AFRS) [7].
Invasive aspergillosis is further divided into invasive pulmonary aspergillosis 
(IPA), sinusitis caused by Aspergillus spp., disseminated aspergillosis, and several 
types of invasive aspergillosis with the involvement of single organs [5, 6]. In 
transplant recipients and other immunocompromised patients, the most common 
clinical form of aspergillosis is invasive pulmonary aspergillosis, which untreated or 
unsuccessfully treated can lead to systemic dissemination to other organs and sys-
tems, for example, brain, heart, or the bones [1, 2]. In contrast, paranasal sinuses, 
larynx, eyes, ears, and the oral cavity are often involved in primary aspergillosis [2].
Invasive aspergillosis is the most common mold infection, particularly among 
immunocompromised patients. Patients subjected to allogeneic hematopoietic stem 
cell transplantation (alloHSCT) constitute a group of patients with the highest risk of 
systemic fungal infections, caused by both Candida spp., as well as Aspergillus spp.  
[5, 6]. Factors predisposing to the invasive aspergillosis are prolonged neutropenia 
(<500/μl for >10 days) and lymphopenia (mainly affecting CD4+ cells) [5, 8–12]. 
Frequency of invasive infections caused by Aspergillus spp. is on the increase in patients 
undergoing chemo- and/or radiotherapy, treated with corticosteroids or immunosup-
pressive agents, as well as in patients with acquired immune deficiency syndrome 
(AIDS) or congenital deficiencies of the immune system, such as chronic granulo-
matous disease [1, 8, 10, 12–14]. Patients at the extremes of age (>60 and neonates), 
persons with chronic malnutrition, and individuals on total parenteral nutrition have 
fungal infections more often than patients in other groups [8, 10, 13]. Surgical pro-
cedures, particularly thoracic or abdominal surgery and solid organ transplantation, 
and the use of central venous catheters or dialysis catheters are linked to endogenous 
and exogenous infections, including those caused by Aspergillus spp. [1, 5, 6, 8–11]. 
Underlying diseases, such as diabetes, kidney, and/or liver failure, and chronic obstruc-
tive pulmonary disease (COPD) also predispose to invasive fungal infections [1, 8].
2. Etiology of invasive aspergillosis
Aspergillosis is caused by opportunistic molds of the genus Aspergillus, which 
contains more than 300 species; however, only relatively few of them are known to 
cause human diseases [12]. These fungi are ubiquitous in soil, plants, and decaying 
organic debris, as well as in household dust and building materials [1]. Hospitalized 
immunocompromised patients are at risk of aspergillosis during construction or 
renovation works at the hospital. Fungi Aspergillus spp. (like other molds), produce 
conidia that are easily aerosolized [12]. Inhaled conidia colonize the respiratory 
system of the host in whom—depending on the degree of immunosuppression—
various clinical forms of aspergillosis may develop. Rarely, aspergillosis results from 
ingestion of the spores or their direct inoculation into the wounds [12].
The most common etiological agent of invasive aspergillosis with a high morality 
is A. fumigatus, responsible for the majority (up to 90%) of cases in humans  
[1, 12, 15–19]. It is followed by A. flavus, which causes up to 10% of cases of 
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bronchoalveolar aspergillosis [18]. This species also is responsible for most cases 
of aspergillosis with sinus and skin involvement [1]. It appears that A. flavus 
survives better than other Aspergillus spp. in a dry and hot climate; therefore, it is 
mainly isolated in Asia, Middle East, and Africa [17]. Other species of the genus 
Aspergillus, such as A. niger, A. nidulans, A. terreus, A. versicolor, A. calidoustus, and 
A. ustus cause invasive infections less frequently; however, they are of importance 
in immunocompromised patients [12, 18, 20, 21]. Strains of A. niger colonize the 
respiratory tract and are etiological agents of most cases of external otitis [1]. 
According to the Prospective Antifungal Therapy Alliance® (PATH Alliance ®) 
registry, in a cohort study of 960 cases of proven/probable IA, A. fumigatus (72.6%) 
was the most predominant species, followed by A. flavus (9.9%), A. niger (8.7%), 
and A. terreus (4.3%) [12]. Recently, an increasing frequency of infections caused 
by environmental species of Aspergillus (of unknown significance in medicine) is 
being reported [21].
Apart from Aspergillus species other than A. fumigatus, recently attention is 
being focused on the strains classified in the section Fumigati (A. fumigatus com-
plex), for example, Neosartorya udagawae (A. udagawae) [18, 22]. They may cause 
similar diseases as A. fumigatus sensu stricto; however, duration of illness may be 
prolonged (even sevenfold) [22]. It appears that actual prevalence of these cases 
may be underestimated, as these strains are often misidentified because they cannot 
be distinguished from A. fumigatus sensu stricto by conventional morphological tests 
[18]. Moreover, the outcome of treatment of these infections may be unfavorable, 
as strains belonging to A. fumigatus-related species (the section Fumigati) often 
show some level of intrinsic resistance to azoles and other antifungal drugs, with 
the minimum inhibitory concentrations (MICs) of various antifungals for these 
isolates higher than those for A. fumigatus, which is usually susceptible to azoles 
[22]. However, in a recent multicenter prospective study, the rate of azole resistance 
among A. fumigatus isolates was relatively high—3.2%, out of which 78% were A. 
fumigatus sensu stricto with a mutation of the cyp51A gene, while the remaining 22% 
were the related species (A. lentulus, A. thermomutatus, and A. udagawae) [23].
In clinical practice A. lentulus, A. udagawae, A. viridinutans, and A. thermomu-
tatus (Neosartorya pseudofischeri), A. novofumigatus and A. hiratsukae have been 
linked etiologically to such refractory cases of IA [18]. These A. fumigatus complex 
strains are characterized by lower virulence ascribed to a lower thermotolerance 
and different profiles of secondary metabolites with decreased production of 
mycotoxins, such as gliotoxin [18]. Definitive identification of these cryptic spe-
cies requires specific sequencing analyses of the beta-tubulin or calmodulin genes, 
which are not readily available. Clinical microbiologists should, therefore, be aware 
of such cryptic species of Aspergillus and the methods of their differentiation from 
A. fumigatus—defect in sporulation, unusual susceptibility profile to antifungals, as 
well as multiplex PCR assays and matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF MS) technique [18].
3. Clinical forms of invasive aspergillosis
Molds of the genus Aspergillus may cause a wide variety of clinical entities, rang-
ing from asymptomatic colonization, allergic bronchopulmonary aspergillosis, and 
chronic pulmonary aspergillosis to severe (even fulminant) invasive infections in 
almost every organ or system in the body of the host, including (but not limited to) the 
lungs, heart, central nervous system, and the sinuses [5, 18, 19, 24]. The most common 
clinical form of invasive diseases caused by Aspergillus spp. is pulmonary aspergillosis, 
which in about 50% of cases spreads to other anatomical locations, including the 
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brain, liver, kidneys, endocardium, bones, and gastrointestinal tract [8, 10, 13, 19, 25]. 
Aspergillosis may also affect the paranasal sinuses, the ear, or the eyeball [13].
The spectrum of aspergillosis is determined by the host’s immune status (par-
ticularly severe and prolonged neutropenia) and the virulence of Aspergillus strain 
causing the infection [5, 6, 12, 13]. In immunocompetent persons, molds of the 
genus Aspergillus mainly cause allergic symptoms and chronic pulmonary aspergil-
losis, without invasion and destruction of the host’s tissues [12]. In the chronic 
pulmonary aspergillosis, usually a preexisting pulmonary condition is observed, 
such as preformed cavity in the lung (resulting from tuberculosis, sarcoidosis, or 
other necrotising process), in which an aspergilloma (or a fungus ball) is being 
formed (chronic cavitary pulmonary aspergillosis) [12]. Allergic bronchopulmo-
nary aspergillosis (ABPA) is a disease that arises from a hypersensitivity reaction to 
Aspergillus antigens and most often develops in patients who have asthma, atopy, 
or cystic fibrosis [8, 12, 26]. Another form of aspergillosis, characterized by a local 
invasion of the lung parenchyma; however, without invasion or dissemination 
to other organs, is called subacute invasive aspergillosis (or chronic necrotizing 
pulmonary aspergillosis) [12].
Invasive aspergillosis is a life-threatening infection and a major cause of death 
in immunocompromised patients, particularly hematopoietic stem cell transplant 
recipients, but may be fatal even in immunocompetent individuals, with the death 
rate of 40% for pulmonary disease, 90% for disseminated disease, and practically 
100% for disseminated disease with the central nervous system (CNS) involvement 
[1, 19]. According to the literature, invasive aspergillosis occurs in 1–15% of the 
solid organ transplant recipients, in whom mortality rates due to this disease range 
from 65 to 92% [1]. However, currently these indices improve in these patients due 
to advances in immunosuppressive regimens and transplantation practices, as well 
as frequent use of antifungal prophylaxis.
Recent reports indicate that invasive aspergillosis is being increasingly diag-
nosed in patients without above-mentioned severe neutropenia—particularly in the 
lung transplant recipients, patients hospitalized in the intensive care unit or treated 
with corticosteroids [9, 11, 27]. Also, individuals with chronic obstructive pulmo-
nary disease (COPD), liver failure, and other underlying diseases are listed in this 
group [8, 11, 20]. It has been reported that in ICU patients with invasive pulmonary 
aspergillosis 40–80% of them do not have any malignancy or other classical risk 
factors for this infection [8, 20]. Moreover, in contrast to patients with neutropenia, 
in ICU patients the symptoms of aspergillosis are atypical; therefore the diagnosis 
of this infection may be delayed or omitted, according to the autopsy studies [11, 
15, 28]. Tejerina et al. showed that among 893 deceased patients, previously treated 
in ICU, only 40% (10 out of 25) had invasive aspergillosis diagnosed ante mortem 
[11]. Problems with proper diagnosis of invasive asergillosis, and therefore a delay 
in administration of effective antifungal therapy, are undoubtfully linked to a high 
mortality rate in this group of patients (30–40%), which may even exceed 90% 
despite lack of severe immunosuppression in these individuals [15, 27, 29].
3.1 Aspergillosis of the oral cavity and the upper respiratory tract
As mentioned earlier, aspergillosis affects mainly the lungs; however it may also 
be diagnosed in the upper respiratory tract and the oral cavity [2, 30]. Orofacial 
aspergillosis is relatively common in oncohematological patients undergoing 
chemotherapy [2].
Aspergillosis of the larynx is very rare, with only a few cases reported in the 
literature [31]. Usually, it is secondary form of this disease, while primary aspergil-
losis of the larynx is even rarer. Risk factors for aspergillosis of the larynx comprise 
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the use of inhaled or systemic steroids, prolonged antibiotic therapy, and underly-
ing immunosuppression [31]. It should be emphasized that these lesions may mimic 
malignancy or a premalignant condition, while proper diagnosis and administration 
of antifungal therapy, as well as elimination of the risk factors (if possible), are 
effective in the elimination of this condition [31].
It also appears that chronic tonsillitis may be caused by Aspergillus spp. In a study 
of 75 symptomatic children who underwent a tonsillectomy, in 9 (12%) of them 
Aspergillus was detected on histological examination of the removed tonsils [30].
Aspergillus spores may be deposited in the oral cavity upon inhalation or during 
dental procedures, for example, tooth extraction [3]. The fungus may then spread 
further into the sinuses as odontogenic infection [32, 33]. The infection may also 
become established in the oral cavity itself.
In oral aspergillosis, the lesions are usually located on the palate or posterior 
tongue [2]. They are yellow or black, with a necrotic ulcerated base. The hyphal 
elements of Aspergillus fungus may invade the oral mucosa through the release of 
various toxins, such as proteases, phospholipases, hemolysins, gliotoxin, aflatoxin, 
phthioic acid, and many others. Subsequently, they penetrate the blood vessels, pro-
ducing thrombosis, infarction and necrosis, and then systemic spread follows [2].
3.2 Aspergillosis of the nose and paranasal sinuses
Paranasal sinuses may be colonized or infected by fungi, while infection can 
be invasive (acute or chronic) or noninvasive (allergic sinusitis and aspergilloma) 
[18]. In invasive aspergillosis of the sinuses, there are rapid (within a few days) 
destructions of the sinuses, the nasal cavity, and the adjacent structures, such as the 
orbit and the brain [18]. Aspergillus spp. may also cause allergic Aspergillus sinusitis 
(AAS), which results from a hypersensitivity reaction to the presence of the fungus 
in the sinus [26]. The hallmark of AAS is demonstration of fungal elements in the 
material obtained from the sinus [26].
It is estimated, that fungal sinusitis constitutes 6–9% of all cases of rhinosi-
nusitis. Among fungi causing sinusitis, the most common is Aspergillus spp. [18]. 
Aspergillosis of the paranasal sinus should be suspected in patients with refrac-
tory or recurrent sinusitis. Apart from the sinuses, aspergillosis may also affect 
the nasal cavity, from which the infection can spread to the CNS (rhinocerebral 
aspergillosis).
The maxillary sinus is more often affected than other paranasal sinuses. 
However, it is frequently misdiagnosed, even as malignancy [3, 18, 34]. Untreated 
infection may spread to the other structures in the head [35]. Invasive aspergillosis 
of the maxillary sinus should be considered in patients with maxillary sinusitis 
which does not respond to standard therapy with antibiotics, even in immunocom-
petent patients [3].
From the paranasal sinuses, Aspergillus infection may spread locally into the 
vasculature and the brain, leading to cavernous sinus thrombosis and a variety of 
central nervous system manifestations and to other locations, for example, the orbit 
[36]. In these cases, computed tomography (CT) or magnetic resonance imaging 
(MRI) and biopsy of any lesion located in the sinuses or the nasal cavity in high-risk 
patients is mandatory [19]. Intracranial and intraorbital extension decreases the 
survival rate of these patients [3].
Factors which predispose immunocompetent individuals to fungal infections 
in the sinuses include polyps and blocked drainage of secretions [3]. Additional risk 
factors for fungal sinusitis, including Aspergillus, are reported in immunocompro-
mised patients and individuals with various underlying diseases, such as neutropenia, 
immunosuppressive therapy, corticosteroids, uncontrolled diabetes mellitus, 
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trauma, burns, and radiation therapy [3]. In these patients, particularly with 
hematological malignancies and in transplant recipients, Aspergillus may cause an 
invasive infection as aggressive in its clinical course as those caused by Zygomycetes 
[19]. Invasive fungal sinusitis is potentially fatal, with an extremely high mortality 
rate, particularly in immunocompromised patients [3]. Therefore invasive aspergil-
losis of the paranasal sinuses has to be recognized and treated to avoid significant 
mortality in immunocompromised patients, particularly in transplant recipients 
[3]. It should be suspected in cases of purulent rhinosinusitis not responding to 
repeated courses of antibiotics, and on the basis of radiological features.
Therapy of fungal sinusitis depends on its clinical form. In cases of Aspergillus 
fungal ball of the paranasal sinuses, surgical removal alone can be sufficient [5, 6]. 
Enlargement of the sinus opening may be needed to improve drainage and prevent 
further recurrence of sinusitis [5, 6]. In invasive aspergillosis apart from surgery, 
also systemic antifugal therapy is recommended.
3.3 Aspergillosis of the lower respiratory tract
Within the lower respiratory tract, Aspergillus infection may affect the larynx, 
trachea, and bronchi (tracheobronchitis), as well as lung parenchyma (pulmonary 
aspergillosis). In rare cases, Aspergillus pleuritis has been reported [19].
The lungs are affected in up to 92% of all cases of invasive aspergillosis [19]. 
Invasive pulmonary aspergillosis is a clinical entity characterized by invasion of the 
fungal hyphae into the blood vessels (angioinvasion), which subsequent hemop-
tysis. Other symptoms comprise nonproductive cough, pleuritic pain, low-grade 
fever, and dyspnea [19]. However, in the early stages of the disease, both clinical 
symptoms and radiological findings may be nonspecific, so proper diagnosis and 
treatment may be delayed, resulting in increased mortality in this group of patients.
The frequency of invasive pulmonary aspergillosis has significantly increased 
in recent years due to a growing number of immunocompromised patients [8, 37]. 
This clinical entity most often occurs in patients with different forms of immuno-
suppression, for example, hematological malignancies, profound and prolonged 
neutropenia, or corticosteroid therapy, as well as organ transplantation, autoim-
mune and inflammatory conditions, in critically ill patients, and those with chronic 
obstructive pulmonary disease (COPD) [8, 37]. In about 50% of patients with 
invasive pulmonary aspergillosis, the infection spreads to other anatomical sites, 
such as the brain, liver, kidneys, or the gastrointestinal tract [8, 10, 13, 19, 25].
An uncommon clinical form of IA is an isolated invasive Aspergillus tracheo-
bronchitis (iIATB), in which fungal infection is limited predominantly or entirely 
to the tracheobronchial tree [19, 38]. It has been mainly reported in lung- and 
heart-lung transplant recipients. Wu et al. reviewed 19 cases of this disease and 
concluded that iIATB occurs in moderately or nonimmunocompromised patients 
with impaired airway structures or defense functions and it may be an early period 
of invasive pulmonary aspergillosis [38]. Early diagnosis and effective antifungal 
treatment were linked to a favorable prognosis; however, 5 out of 19 (26.3%) 
patients died.
Other forms of Aspergillus infection of the lungs comprise chronic necrotizing 
aspergillosis, which is described in patients with chronic lung disease or low degree 
immunodeficiency as a locally invasive disease, as well as aspergilloma usually 
found in individuals with previously formed cavities in the lungs [8, 12].
As mentioned earlier, symptoms of the pulmonary disease may result not from 
actual infection, but allergic reaction of the host to the presence of Aspergillus 
in the bronchial tree—allergic brochopulmonary aspergillosis (ABPA) [12, 26]. 
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This immunologically mediated disease occurs predominantly in patients with 
asthma, atopy, and cystic fibrosis (CF) [8, 12, 26].
3.4 Aspergillosis of the central nervous system
Aspergillosis of the brain (cerebral aspergillosis) is usually a part of the dissemi-
nated disease after hematogenous spread of infection from the lungs, but rarely 
it may represent an isolated disease of the central nervous system (CNS) [19]. It 
is reported in 10–15% of patients with invasive pulmonary aspergillosis [39]. The 
most common risk factors comprise neutropenia and other forms of immunosup-
pression and transplantation surgery [19]. Cerebral aspergillosis usually presents as 
a single or multiple brain abscess, also as cerebral vasculitis and cerebral infarcts, 
while meningitis is rare [19]. Brain abscesses are common in HSCT recipients, while 
relatively rare in solid organ transplant (SOT) recipients [40, 41]. CT and MRI are 
recommended in patients in whom cerebral aspergillosis is suspected [42]. Among 
all types of IA, brain aspergillosis has the worst prognosis, with mortality rate usu-
ally exceeding 90% (up to 100%), however early and proper treatment improves 
the prognosis in these patients and significantly increases their survival rates [19].
Aspergillosis of the CNS may also present as rhinocerebral aspergillosis, particu-
larly in patients with underlying malignancies and neutropenia, HSCT recipients, 
and patients with diabetic ketoacidosis [37]. Symptoms usually comprise fever, 
nasal or sinus congestion or pain, nasal discharge, unilateral facial swelling, and 
headaches [37]. Necrotic lesions may be seen on the hard palate and in the nasal 
cavity. The spread of infection may lead to ophthalmic complications, such as 
ptosis, proptosis, and vision disturbances [37].
3.5 Invasive cardiac aspergillosis
Invasive cardiac aspergillosis may present as endocarditis, myocarditis, pericar-
ditis, mediastinitis, septic thrombophlebitis, and infections of aortic grafts—also in 
transplant recipients [5, 6, 43, 44].
Endocarditis caused by Aspergillus spp. is a severe form of fungal endocarditis 
[45, 46]. The mortality rate is high and surgery is usually required [19, 45–47]. It is 
very rare, but in recent years, the incidence of this form of aspergillosis is increas-
ing, due to a rise in the frequency of its risk factors—the use of invasive procedures 
involving the heart, cardiac surgery with replacement of the heart valves, implanta-
tion of cardiac devices, organ transplantation, drug abuse, or administration of 
immunosuppressive therapy [19, 45]. Pierrotti and Baddour analyzed mold-related 
endocarditis in 3939 patients (the majority of cases were caused by Aspergillus spp.) 
and found the following risk factors: underlying cardiac abnormalities (41%), pros-
thetic heart valves (39%), malignancy (18%), solid-organ transplantation (18%), 
and bone marrow transplantation (18%) [47]. In a study by Paterson et al., 26% of 
cases of infective endocarditis occurring within a month of solid organ transplanta-
tion were caused by Aspergillus [48]. Woods et al. found that the most common 
predisposing factors for Aspergillus endocarditis in 29 patients were corticosteroid 
therapy (55%), prolonged antibiotic treatment (31%), hematological malignancy 
(28%), and chemotherapy and cytotoxic therapy (28%) [49].
In the course of Aspergillus endocarditis, mitral and bicuspid valves (native 
or prosthetic) are most often affected [19, 46, 50, 51]. Fungal vegetations may be 
formed on the heart valves, which subsequently may cause embolism blocking the 
arteries. Gumbo et al. reported that vegetations were revealed on the heart valves 
in 78% of the cases in which echocardiography was performed, while embolic 
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episodes were seen in 69% of patients with Aspergillus endocarditis, and a new 
or changing heart murmur—in 41% of them [52]. In a recently published study, 
Meshaal et al. showed that aortic abscess or pseudoaneurysm was one of the 
strong predictors of Aspergillus endocarditis [45]. However, it should be noted that 
Aspergillus endocarditis may be difficult to diagnose because blood cultures are 
usually negative, while fever is absent in 26% of patients with this disease [19, 45]. 
Aspergillus endocarditis should, therefore, be suspected in patients with underlying 
immunosuppression, hematological malignancies, recent cardiothoracic surgery, 
intravenous drug use, systemic or pulmonary emboli with negative blood cultures, 
and vegetation on echocardiography [24]. Diagnosis should be confirmed by 
histology and mycological culture of tissue or vegetation samples [24]. Delayed or 
erroneous diagnosis of Aspergillus endocarditis contributes to incorrect manage-
ment of patients. Early surgical replacement of an infected valve and prolonged 
administration of antifungal therapy (which may be lifelong) are recommended to 
prevent embolic complications, valvular decompensation, and further spread of 
the infection [5, 6, 24, 43, 44].
Heart muscle may be affected by Aspergillus infection in the form of myocarditis 
or cardiomyopathy [53, 54]. This form of disease usually results from hematogenous 
spread of infection and is characterized by the presence of abscesses. Pericarditis 
caused by Aspergillus spp. has been described, also in transplant recipients [43, 55].
3.6 Ocular aspergillosis
Aspergillosis of the eye may take a form of fungal keratitis, endophthalmitis, or 
invasive aspergillosis of the orbit. All structures of the eyeball may be affected—
eyelids, conjunctivae, lacrimal apparatus, cornea, sclera, or uvea. Aspergillus 
dacryocystitis is a rare complication of aspergillosis of the paranasal sinuses [56]. 
Clinicians must be aware that the clinical course of ocular aspergillosis may range 
from asymptomatic infection or slowly developing disease to rapidly progressive 
infection, with a fulminant course and fatal outcome [56].
Fungal keratitis often presents as a corneal ulcer, which results from mechani-
cal injury of the cornea, with subsequent necrosis. In a recent study, Manikandan 
et al. examined a total of 500 corneal scrapings, collected from patients in whom 
mycotic keratitis was suspected, out of which 68 (13.6%) were positive for 
Aspergillus spp. [57].
Endophthalmitis may be a complication of surgical procedures or may result 
from hematogenous spread from other sites of infection. Endogenous Aspergillus 
endophthalmitis is mainly reported in severely immunocompromised patients, 
transplant organ recipients, patients after heart valve replacement, and in oncohe-
matological patients [58–60].
Orbital invasive aspergillosis is a rare infection, which most often results from 
dissemination of the infection from the nose or paranasal sinuses. It may take an 
acute or chronic form. This form of IA usually presents with a severe orbital pain, 
paralysis of the oculomotor nerve and visual impairment. Ophthalmic complica-
tions, such as ptosis, proptosis, and vision disturbances may result from the spread 
of infection in rhinocerebral aspergillosis [37].
3.7 Aspergillosis of the genitourinary tract
Aspergillosis of the urinary tract is relatively rare. In immunocompromised 
patients, such as kidney transplant recipients, frequency of this form of aspergil-
losis amounts to only 0.5–2.2%, but is fatal in >88% of patients [61]. Urinary tract 
aspergillosis may also be a complication of surgical procedures, such as lithotripsy, 
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urinary tract instrumentation, or ureteric stenting, particularly in immunocom-
promised patients [62–65]. Renal aspergillosis is being occasionally reported with 
obstruction of one or both ureters [19]. Localized aspergillosis of the renal graft was 
reported in a child 5 months after kidney transplantation [61]. A case of urinary 
tract aspergillosis presenting as an aspergilloma of the urinary bladder has also been 
described [66].
Aspergillosis of the genital tract has been rarely reported [67–69]. In women, it 
may give the symptoms resembling a pelvic inflammatory disease.
3.8 Other clinical forms of aspergillosis
Other clinical forms of aspergillosis—apart from above-mentioned—are very rare 
and comprise gastrointestinal aspergillosis, cutaneous aspergillosis, Aspergillus perito-
nitis, osteomyelitis, and septic arthritis, as well as Aspergillus ear infections [5, 6, 19, 37].
Gastrointestinal aspergillosis is mainly reported in patients who are transplant 
recipients or severely malnourished [37]. It results from ingestion of Aspergillus spp. 
spores. The most commonly involved sites are the stomach, colon, and ileum.
Cutaneous aspergillosis is classified as primary or secondary [37]. Primary form 
of the disease is usually reported in patients with burn wounds or surgical wounds. 
This clinical entity is caused by direct inoculation of the fungus or its spores into 
the injured skin [37]. Primary cutaneous aspergillosis has been linked to leukemic 
patients, neonates, transplant recipients, as well as the use of occlusive dressings 
or permanent intravenous catheters [19]. Secondary cutaneous aspergillosis results 
from hematogenous spread of the fungus and therefore represents a disseminated 
form of Aspergillus infection. It may present as nodules or extensive necrotic lesions 
[19]. The mortality rate may be high.
Aspergillus peritonitis is seen in patients undergoing peritoneal dialysis [19]. It 
may be complicated by hemorrhage, perforation, or infarction.
Aspergillus ear infections may present as noninvasive otitis externa (otomycosis) 
or invasive aspergillosis of the ear. Examples of other forms of invasive aspergillosis 
comprise vertebral osteomyelitis (resulting from hematogenous spread, by contigu-
ity or from direct inoculation), septic arthritis, cholangitis, and prosthetic vascular 
graft rejection [19].
Disseminated aspergillosis if defined as the involvement of at least two  
noncontiguous sites in the body, mainly in transplant recipients [19]. Disseminated 
disease has been reported in 9–36% of kidney transplant recipients, 15–20% of lung 
transplant recipients, 20–35% of heart transplant recipients, and 50–60% of liver 
transplant recipients with invasive aspergillosis [70].
4. Aspergillosis in transplant recipients
In patients with immune deficiencies and other risk factors, invasive aspergil-
losis (IA) is a life-threatening infection caused by the opportunistic molds of the 
genus Aspergillus, most often by A. fumigatus [5, 6, 14, 70, 71]. A cohort study of 
960 cases of probable or proven IA reported in the Prospective Antifungal Therapy 
Alliance (PATH Alliance) registry, indicated that 48.3% of patients had hematologic 
malignancy, 29.2% were SOT recipients, 27.9% were HSCT recipients, and 33.8% 
were neutropenic [12]. In these patients, the most common clinical forms of IA are 
invasive pulmonary aspergillosis (IPA) and rhinocerebral aspergillosis [12].
In transplant recipients, particularly in hematopoietic stem cell transplant 
(HSCT) recipients who are severely immunocompromised, invasive aspergillosis is 
not only more common than in other groups of patients, but is also characterized by 
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much more severe and rapidly progressive clinical course, and much higher mortal-
ity [12, 72].
Although prognosis has improved in recent years, IA still remains a significant 
post-transplant complication in solid organ transplant (SOT) recipients [43, 44]. It 
occurs in up to 30% of SOT recipients. Although in recent years the mortality rate 
in transplant recipients decreased from 65–92% to 22%, still an estimated 9.3–16.9% 
of all deaths in transplant recipients in the first year after transplantation can be 
attributed to IA [44].
The incidence of IA differs between different populations of transplant recipi-
ents, and unique risk factors for Aspergillus infections have been identified for vari-
ous types of organ transplant recipients [43, 44]. However, regardless of the type 
of transplantation a major risk factor for the development of IA in SOT recipients is 
the net state of immunosuppression including the intensity of administered immu-
nosuppressive therapy [44].
Regarding the risk of invasive fungal infections (particularly IA) in transplant 
recipients, at present routine antifungal prophylaxis or preemptive therapy is 
recommended in HSCT recipients with prolonged neutropenia or graft-versus-host 
disease (GVHD), and in lung transplant recipients, while targeted prophylaxis 
should be considered in liver and heart transplant recipients [5, 6, 44, 71].
4.1 Hematopoietic stem cell transplant (HSCT) recipients
Invasive aspergillosis remains a major complication following allogeneic HSCT 
(alloHSCT) [73]. The burden of IA has increased significantly in the last 30 years 
as a result of the increased number of patients undergoing immunosuppressive 
therapy for hematological malignancies and HSCT [14]. It is estimated that IA is a 
leading cause of fatal outcomes in HSCT patients, accounting for 10% of all deaths 
in this group of patients [14].
In the recipients of alloHSCT, IA can occur during the neutropenic pre-
engraftment phase (early IA) or during the post-engraftment period (late IA) [14]. 
Although IA remains an important complication after allogeneic transplantation, 
regardless of the type of conditioning regimen, early IA is more common in patients 
undergoing myeloablative transplantation due to extensive chemotherapy and 
radiation used to destroy the native bone marrow, and prolonged neutropenia which 
results from this treatment [14, 74]. On the other hand, non-myeloablative HSCT 
comprises a shorter neutropenic period and therefore, a decrease in the incidence of 
early IA. However, a higher risk of GVHD in this group of patients and the therapies 
given for this condition caused a shift to late IA, diagnosed increasingly during the 
post-engraftment period [14]. It should be noted that the risk period for late IA, 
associated with GVHD, can last for months to years, so prophylactic and monitoring 
procedures must be implemented over a long period. Carvalho-Dias et al. analyzed 
24 cases of proven and probable invasive aspergillosis among HSCT recipients and 
reported, that 83% of the patients died due to invasive fungal infection within 
60 days of follow-up [72].
Kojima et al. compared the incidence of IA and mortality rates due to this 
disease in 664 recipients of alloHSCT—486 conventional stem cell transplantation 
(CST) patients and 178 reduced-intensity stem cell transplant (RIST) recipients. 
The overall incidence of IA in all 664 recipients of alloHSCT was 35 (5.3%) [74]. 
Despite significant differences in the estimated 3-year incidence of IA in CST 
group (4.5%) and RIST population (8.2%) (P = 0.045), the mortality rates were 
similar in both groups (76 and 86%, respectively). However, the median onset of 
IA after RIST was day 127, which was significantly later than that after CST—day 
97 [74]. Furthermore, a multivariate analysis showed that IA was associated with 
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age > 50 years and the presence of acute or chronic GVHD [74]. In another study, 
Labbe et al. analyzed the risk factors for IA in 125 alloHSCT recipients with nonmy-
eloablative (NMA) regimens, who received a 6/6 matched sibling NMA HSCT and 
were treated homogenously [73]. IA developed in 13 patients (5 proved, 6 prob-
able, and 2 possible IA), at 44–791 days (median 229 days) after NMA HSCT. The 
risk of IA was calculated as 7% at 1 year, 11% at 2 years, and 15% at 3 years after 
NMA alloHSCT [73]. It was concluded that in NMA HSCT recipients the risk of IA 
increases over time and is significantly associated with intestinal GVHD, therefore 
these patients should be monitored for this complication and administration of 
antifungal prophylaxis with activity against molds should be considered [73].
4.2 Lung and heart-lung transplant recipients
In lung transplant recipients, invasive aspergillosis is the predominant fungal 
infection [44, 71, 75]. In the past, the incidence of IA in this group of patients was 
reported in the range of 4.0–23.3%, however, newer studies point to a lower frequency 
of this disease [44]. On the other hand, the time from lung transplantation to the 
onset of IA becomes longer due to the use of antifungal prophylaxis in the early post-
transplant period. Therefore the median time to IA onset has increased from 120 days 
post-transplant to 483 or 508 days post-transplant reported in recent studies [44].
The most common species linked to the etiology of IA in lung transplant recipi-
ents is Aspergillus fumigatus. In an international, multicenter, retrospective cohort 
study of 900 consecutive adult lung transplant recipients with 4 years of follow-up, 
79 patients developed 115 episodes of IA [75]. Aspergillus fumigatus was isolated in 
72 of 115 (63%) episodes [75]. In a retrospective study of 251 lung transplant recipi-
ents, Aspergillus was isolated from 86 (33%) cases including 50 patients colonized 
with Aspergillus spp., 17 recipients with tracheobronchitis, and 19 cases of IA [76]. 
These authors reported that isolation of Aspergillus spp. from respiratory samples 
preceded acute rejection of the graft, therefore it may be a marker of threatening 
graft rejection and/or inflammation of the airways [76].
The significance of the patient’s airway colonization with Aspergillus spp. before 
lung transplantation remains controversial. Some authors indicate its importance 
within the first year after lung transplantation, if the recipient was colonized in 
the period of 6 months before lung transplantation, while others did not find any 
significant link between Aspergillus pre-transplant colonization and occurrence of 
IA in the post-transplant period [44, 75–77]. Other risk factors for IA, which are 
unique to lung transplant recipients, comprise bronchial anastomotic leaks and 
other complications within the surgical site, airway narrowing, allograft dysfunc-
tion and/or graft ischaemia, reperfusion injury, CMV infection, bronchiolitis, 
and requirement for more intensive immunosuppressive therapy to prevent graft 
rejection [44, 76]. In lung transplant recipients, recovery of Aspergillus spp. from a 
respiratory tract sample warrants bronchoscopy to exclude the presence of tracheo-
bronchitis [44].
It should be beared in mind that in lung transplant recipients there is a continu-
ous exposure of the graft to the external environment through the airways, with 
impaired defense mechanisms (decreased mucociliary function, weakened cough 
reflex) in the early postransplant period [44].
In lung transplant recipients, there is a transient devascularization of the bron-
chial anastomotic site, which may contribute to ischemic injury and necrosis. This 
is a risk factor for development of ulcerative tracheobronchitis—a locally invasive 
form of IA involving the anastomotic site, the trachea, and the bronchi [44, 78]. 




In the literature reports, the mortality rate of lung transplant recipients with IA 
ranges from 23 to 29% in individuals with tracheobronchitis to as high as 67–82% in 
patients with invasive pulmonary aspergillosis, but according to some estimates at 
present, it could be as low as 20% [44]. In a follow-up study of 251 lung transplant 
recipients, Aspergillus infection was associated with a reduced 5-year survival rate 
of these patients [76]. Prognosis is worse in patients with aspergillosis of the central 
nervous system or with disseminated disease [71].
4.3 Heart transplant recipients
According to the literature, the incidence of invasive aspergillosis in heart trans-
plant recipients ranges from 1 to 14% [44, 79]. In this population, the risk factors 
for IA comprise isolation of Aspergillus fumigatus from bronchoalveolar lavage fluid, 
disease caused by cytomegalovirus, reoperation, and post-transplant hemodialysis 
[44]. The mortality rate in heart transplant recipients with invasive aspergillosis 
remains high—in the range of 66–88% [44, 79–81].
Invasive pulmonary aspergillosis remains the most common clinical presenta-
tion of this disease, particularly in early-onset IA (≤3 months after transplanta-
tion), while in late-onset IA, there is a higher frequency of disseminated disease 
and involvement of the central nervous system and other extrapulmonary sites [79, 
80]. In an analysis of 455 heart transplant recipients, in whom 8 cases of IA have 
been diagnosed, all had invasive pulmonary form of the disease [79]. Risk factors 
for early-onset IA (within ≤3 months after heart transplantation), comprised 
hemodialysis, thoracic reoperation, and the presence of another case in the institu-
tion within the preceding 3 months [79]. For late-onset IA in this population of 
heart transplant recipients, hemodialysis and augmented immunosuppression were 
identified as risk factors [79]. In the clinical course of these cases, predominated 
septic shock and multiple organ dysfunction syndrome (MODS), nonspecific clini-
cal and radiographic findings, as well as rapid (at a median of 11 days after diag-
nosis) mortality despite administration of antifungal therapy with activity against 
molds [79]. In a study by Montoya et al., none of the heart transplant recipients 
with either invasive pulmonary aspergillosis or invasive extrapulmonary aspergil-
losis had neutropenia [81]. Therefore, even in the absence of neutropenia invasive 
pulmonary aspergillosis should be suspected, particularly within the first 3 months 
of transplantation in heart transplant recipients who have fever and respiratory 
symptoms, a positive result of culture of respiratory secretions, and abnormal 
radiological findings (particularly nodules) [81].
A study of 479 consecutive heart transplant recipients in a single institution 
revealed a decrease in the incidence of IA from 8.7% (24/277) in the period 1988–
2000 to 3.5% (7/202) in 2001–2011 [80]. Overall the incidence of IA in the studied 
group of heart transplant recipients was 6.5% (31 of 479). However, the authors 
report that four of seven cases were diagnosed as an outbreak, which indicates that 
favorable conditions for an infection with Aspergillus spp. may be present in a hospi-
tal [80]. Over the study period, there was a decrease in the mortality rate among the 
heart transplant recipients with IA from 46 to 0% (p = 0.04) [80]. The authors also 
noted a higher mortality rate in late-onset IA cases (63%) in comparison to early-
onset IA (26%, p = 0.09) [80].
4.4 Liver transplant recipients
Invasive aspergillosis is reported in 1.0–9.2% of the liver transplant recipients. 
Mortality rates have decreased from 83–88% in earlier studies to 33–65% in more 
recent reports [44]. However, they remain very high in patients who develop invasive 
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aspergillosis after liver retransplantation (82.4%), particularly in those undergoing 
surgery later than 30 days after primary liver transplantation (100%) [44].
Risk factors for invasive fungal infections, including aspergillosis, in these 
patients, comprise retransplantation (30-fold higher risk) and renal dysfunction, 
particularly requiring any form of renal replacement therapy (15- to 25-fold higher 
risk) [44]. Furthermore, transplantation for fulminant hepatic failure, pretrans-
plant corticosteroid therapy, cytomegalovirus (CMV) infection, and prolonged 
intensive unit care stay are other risk factors associated with invasive aspergillosis 
in liver transplant recipients [44]. It is underlined that liver transplant recipients 
are particularly susceptible to disseminated and central nervous system invasive 
aspergillosis [44].
Previously most invasive fungal infections in liver transplant recipients occurred 
within the first month after transplantation (the median time to onset was reported 
as 16–17 days), however, in recent years, they are usually diagnosed in the late 
period (>90 days) after liver transplantation. After renal replacement therapy and 
retransplantation, the median time to onset of IA was reported as 13 and 28 days, 
respectively [44].
4.5 Kidney transplant recipients
Invasive aspergillosis has been reported in 0.7–4.0% of the renal transplant 
recipients [44]. It should be emphasized that despite a relatively low overall inci-
dence of IA in comparison to other solid organ transplant (SOT) recipients, the 
mortality rate is high in these patients—in the range of 67–75% [44]. Risk factors 
for invasive aspergillosis in kidney transplant recipients are the following: potent 
immunosuppressive therapy, leukopenia, prolonged and/or high dose corticosteroid 
therapy, longer duration of renal replacement therapy in the pretransplant period, 
and graft failure requiring hemodialysis [44, 82].
In a recent study, Desbois et al. analyzed the outcome of IA in kidney transplant 
recipients in the era of voriconazole availability [83]. Unfortunately, they concluded 
that the prognosis of patients with IA after renal transplantation is still poor, and 
even if the patients survive, the risk of graft loss is high [83].
5. Mycological diagnostics
The diagnosis of invasive aspergillosis remains a significant challenge [19]. It 
is usually based on a histopathological evidence of tissue invasion, in conjunc-
tion with an isolation of Aspergillus spp. in culture of the biopsy material or other 
clinically relevant specimen, as well as compatible clinical signs and symptoms in a 
patient with recognized risk factors. Imaging examinations (radiographic, com-
puted tomography, and magnetic resonance), as well as serological tests (detection 
of fungal antigens and antifungal antibodies), provide only additional information 
and should be interpreted in conjunction with the clinical picture and the results of 
additional laboratory tests [13, 19, 48].
It should be emphasized that fast detection and identification of the etiological 
agent of infection is of utmost importance as it allows an early start of an effective 
antimicrobial therapy, which improves the patient’s chances to survive.
In mycological diagnostics, the culture of the fungus from the site of infec-
tion and in vitro susceptibility testing of the isolate remain the “gold” standard. A 
diagnosis of invasive pulmonary aspergillosis comprises detection of the fungal 
mycelium with histopathological (with the use of different staining techniques) 
tests and/or positive culture of the relevant material obtained from the lower 
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respiratory tract [5, 6, 13, 15, 19]. In a patient in whom invasive pulmonary asper-
gillosis is suspected, it is recommended to culture a sample of bronchoalveolar 
lavage fluid (BALF), obtained as early as possible during the course of infection 
[5, 6, 13, 19]. It should be emphasized that the result of sputum culture is not an 
unequivocal proof of invasive infection of the lung parenchyma, because it may 
represent only colonization of the respiratory tract by the isolated microorganism. 
It has been reported that among 66 elderly patients in whom Aspergillus spp. was 
cultured from sputum, only 3 individuals had invasive pulmonary aspergillosis 
[84]. In another study, no Aspergillus spp. was cultured from the sputum of 70% 
of patients with invasive pulmonary aspergillosis confirmed with other reliable 
methods [8].
Blood cultures are rarely positive in patients with invasive pulmonary aspergil-
losis [8, 19, 45]. In patients with pulmonary aspergillosis, Aspergillus fungaemia was 
detected in 10.1% (9/89) of them, at a median of 5 days from the onset of clinical 
symptoms [19]. The diagnostic role of Aspergillus fungaemia in patients with an 
invasive form of infection is limited because blood cultures become positive (if at 
all) in the late stage of the disease when a microbiological or clinical diagnosis has 
already been made [19].
In laboratory diagnostics of this form of aspergillosis, detection of Aspergillus 
spp. antigen—galactomannan (GM)—in BALF or in serum, may be useful; 
however, it should be remembered that it could represent a false positive result 
[10, 13, 15, 19, 29]. Detection of another fungal antigen which is a constituent of 
the fungal cell wall—(1–3)-β-D-glucan (BDG)—is a nonspecific marker of fungal 
infection, being positive in many fungal infections apart from aspergillosis [13]. 
Molecular methods (e.g. detection of DNA of the strains classified in the genus 
Aspergillus in blood or BALF using PCR technique) are promising, however at 
present, they are not routinely available in clinical microbiology laboratories, 
and interpretation of their results requires further analyses [13, 19, 85]. Research 
is ongoing on the usefulness of serum interleukin-8 concentration as an auxil-
iary marker in laboratory diagnostics of invasive pulmonary aspergillosis [86]. 
Therefore, it should be emphasized that diagnosis of invasive pulmonary aspergil-
losis requires evaluation of the patient’s clinical status in conjunction with the 
results of various examinations—imaging, histological, and mycological, as well as 
biochemical markers [1, 8, 13, 15, 86].
Laboratory methods currently used in diagnosis of invasive aspergillosis com-
prise three groups of techniques: detection of fungal invasion in histopathological 
examination of tissue sections; direct microscopy and isolation of Aspergillus spp. in 
culture of the clinically relevant samples; and noninvasive methods such as sero-
logical detection of antigens or nucleic material of Aspergillus spp., or detection of 
antibodies [19, 87].
5.1 Histopathological examination of tissue sections
Histopathological examination of biopsy or autopsy tissue sections confirms the 
fungal etiology of invasive infections [1, 5, 6, 13, 15, 19]. Tissue sections are usually 
stained with hematoxylin and eosin, but other staining techniques are also used in 
practice (e.g. Gomori-Grocott methenamine silver stain, periodic acid-Schiff stain) 
[2, 88, 89]. Histopathological tissue sections from a patient with invasive easpergil-
losis of the heart and lung are shown in Sulik-Tyszka et al. [89].
In tissue sections, Aspergillus appears as septate hyphae, with dichotomous 
branching at 45° angles suggestive of Aspergillus spp. [2, 19]. Conidiophores and 
fruiting bodies are rarely seen, except in areas exposed to air, for example, bronchi 
[19]. Invasive lesions are characterized by an area of necrosis and non-caseating 
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granulomatous inflammation. A characteristic feature of invasive aspergillosis is 
trespassing of the the fungus into the blood vessels, with subsequent infarction and 
tissue necrosis.
5.2  Direct microscopic examination, culture, and identification of  
Aspergillus spp.
Clinical samples for isolation of Aspergillus spp. in culture depend on the clinical 
symptoms and suspected localization of infection. In the diagnosis of invasive 
pulmonary aspergillosis, a lung biopsy or a sample of BALF is recommended. 
Other specimens, such as bronchial or endotracheal aspirates, pleural fluid, and 
also sputum may be cultured as well [5, 6, 19]. Blood cultures can be done, but are 
usually negative. In fact, any suspicious lesion (e.g. cutaneous or skeletal) should be 
biopsied and cultured for fungi [19].
The direct microscopic examination allows not only rapid detection of the 
fungus directly in the specimen, but also its preliminary identification.
A universal solid medium for culturing fungi is Sabouraud agar. When culturing 
a sample obtained from a site which is primarily nonsterile, Sabouraud agar supple-
mented with chloramphenicol and gentamicin is used. Czapek-Dox agar and 2% 
malt extract agar are also used, as well as liquid media [19]. Commercially available 
media are recommended in order to standardize the culture methods.
Identification of the isolates belonging to the genus Aspergillus relies on evalu-
ation of the colony morphology and color (both on the upper and reverse sides of 
the agar plate), and diffusion of the pigment into the medium (Figure 1). Matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-
TOF-MS) technique may be used in the identification of Aspergillus spp. and is 
a promising tool, particularly for the identification of rare species of Aspergillus 
[90, 91]. This method allows a rapid and reliable identification of the isolate and 
therefore, an early start of effective antifungal therapy.
Interpretation of the mycological culture results is important and depends on 
the clinical picture [19]. In a routine microbiology laboratory work, most of the iso-
lates of Aspergillus fumigatus do not indicate proven or probable infection. However, 
cultures positive for Aspergillus fumigatus, in the appropriate epidemiological and 
clinical setting, such as highly immunocompromised transplant recipients, are 
strongly associated with the presence or risk of IA and therefore should not be dis-
regarded [19]. Also, the isolation of Aspergillus fumigatus in hematological patients, 
even from nonsterile samples, is generally regarded as potentially significant [19]. 
It has been reported that in heart transplant recipients with suspicion of invasive 
aspergillosis, a culture positive for Aspergillus has a positive predictive value (PPV) 
of 60–70% [92]. Higher PPV (78–91%) was linked to the isolation of Aspergillus 
fumigatus, with a further increase to 88–100% when Aspergillus fumigatus is recov-
ered from a respiratory specimen other than sputum [92].
It should be emphasized that in transplant recipient’s fungal cultures may 
be negative, despite disseminated infection, and in invasive aspergillosis, blood 
cultures are usually negative, even in patients with Aspergillus endocarditis [19].
5.3 Serological testing in the diagnosis of aspergillosis
Serological tests are widely used in the laboratory diagnostics of aspergillosis. 
Conventional methods, such as culture of clinical samples and direct microscopy of 
the specimens, have low sensitivity and may give positive results in the late stages 
of the disease [19]. Furthermore, suitable specimens for these methods may be 
difficult to obtain in severely ill, immunocompromised patients. In recent years, 
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serological techniques are being used increasingly on such specimens, like serum or 
BALF, for detection of fungal antigens (e.g. galactomannan, (1,3)-ß-d-glucan) and 
anti-galactomannan antibodies against Aspergilllus [44]. Detection of galactoman-
nan in BALF or serum is at present recommended in the American and European 
guidelines on laboratory diagnosis of invasive aspergillosis in immunocompromised 
patients [5, 6, 13].
Duration of antifungal therapy may be guided not only by monitoring of 
galactomannan levels, but also by the clinical status of the patient and radiological 
findings.
Figure 1. 
Aspergillus spp. growth on Sabouraud agar. (A) Aspergillus niger; (B) Aspergillus fumigatus; (C) Aspergillus 
flavus.
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5.3.1 Galactomannan (GM)
Galactomannan (GM) is a cell wall component of Aspergillus spp., released from 
Aspergillus hyphae, while they invade the host tissue, and therefore, it is a specific 
marker of this fungus [19]. This test may be helpful in early diagnosis of IA (median 
of 6 days before the symptoms appear) before the infection becomes disseminated 
[19]. Galactomannan can be detected with the use of latex tests (detection level 
15 ng/ml) or more sensitive immunoenzymatic assays, in which 1 ng/ml of GM can 
be detected. Variation in sensitivity of these tests is being reported, which may due 
to the different cut-off values for a positive GM result in Europe (1.5 ng/mL) and 
the USA (0.5 ng/mL) [19].
Galactomannan concentration in the bronchoalveolar lavage fluid, in combina-
tion with other diagnostic tests (e.g. chest CT scan or mycological culture) is recom-
mended as a test for the diagnosis of IA in lung and nonlung transplant recipients 
[71]. Galactomannan in BALF sample has proven superior to serum testing with 
high sensitivity (67–100%) and specificity rates (91–100%) for the diagnosis of 
invasive aspergillosis in lung transplant recipients [44]. In patients with prolonged 
neutropenia and allogeneic stem cell transplant recipients during the early engraft-
ment phase, GM detection is commonly used, and serial screening for GM in serum 
has a high sensitivity and a negative predictive value for IA [13, 14]. However, serial 
screening for GM is not recommended in patients receiving antifungal prophylaxis 
with anti-Aspergillus spectrum of activity [13].
False-positive results of galactomannan detection have been documented in 
up to 13–29% of the liver transplant recipients and in 20% of the lung transplant 
recipients [44]. In the liver transplant recipients, false-positive results of galacto-
mannan tests were more often seen in patients with transplantation for autoimmune 
liver disease, perioperative prophylaxis with β-lactam antibiotics, and requirement 
of dialysis. Most false-positive tests after lung transplantation occurred in the early 
post-transplant period: that is, in 43% within 3 days, in 64% within 7 days, and 
in 79% within 14 days of surgery. False-positive results of galactomannan detec-
tion are linked to several factors, such as antibiotic therapy with specific groups of 
antibacterials (such as some cephalosporins, carbapenems, amoxicillin-clavulanate, 
ampicillin/sulbactam, and piperacillin/tazobactam), cyclophosphamide therapy, as 
well as administration of blood products, albumin or immunoglobulins, or the use 
of cellulose hemodialysis membranes [93, 94].
5.3.2 (1,3)-ß-d-glucan
Detection of (1,3)-ß-d-glucan is a nonspecific test for fungal infection, as it is 
one of the main cell wall polysaccharide components of many fungi [19]. Available 
diagnostic tests are characterized by a high sensitivity and specificity and enable 
detection of (1,3)-ß-d-glucan at the concentration of >1 pg/ml. It has been reported 
that in living-donor, liver allograft recipients, detection of (1,3)-ß-d-glucan was 
useful for the diagnosis of invasive aspergillosis [95]. Several factors have been 
linked to false-positive results of the tests for (1,3)-ß-d-glucan, which are similar to 
those for galactomannan detection [19].
5.4 Molecular methods
At present, molecular diagnostic tests for Aspergillus spp. are not available in 
routine clinical microbiology laboratories, however, in the near future, they will be 
used increasingly, particularly for identification of unusual species, with specific 
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profiles of susceptibility or resistance to antifungals [19, 44, 96]. Recently, PCR 
technique for detection of Aspergillus spp. has been extensively validated and will 
be included in the diagnostic criteria in the revised European Organization for 
Research and Treatment of Cancer/Mycoses Study Group (EORTC-MSG) defini-
tions [97]. A comprehensive review of the molecular diagnosis of invasive aspergil-
losis has recently been published [85].
The majority of molecular methods which can be used in the clinical microbiol-
ogy laboratories are based on PCR technique. These methods are particularly useful 
for testing of lung specimens. It has been reported, that quantitative PCR test used 
for diagnosis of IA with a sample of bronchoalveolar lavage fluid was characterized 
by 67% sensitivity and 100% specificity [98]. Perhaps in the future, quantitative 
PCR tests will also be used to monitor the response to antifungal treatment in 
patients with IA [19].
Fluorescence in situ hybridization-based molecular method is a promising 
approach in the A. fumigatus detection in the tissues [87]. Species identification of 
Aspergillus isolates may be made by β-tubulin and calmodulin gene sequencing [91]. 
Further analyses are needed to evaluate the significance of the results of molecular 
tests in immunocompromised patients suspected of invasive aspergillosis.
6. Treatment of invasive aspergillosis
Successful treatment of invasive aspergillosis comprises early diagnosis of the 
disease, selection of an appropriate antifungal agent active against fungi of the 
genus Aspergillus, and prompt initiation of antifungal therapy, as well as surgical 
debridement, particularly in immunocompromised patients, such as HSCT and 
SOT recipients [3, 44]. Proper pharmacokinetics, pharmacoeconomics, and no 
interactions with other medications (e.g. immunosuppressants) administered to 
the patient are further factors which determine the choice of a proper antifungal 
agent.
At present, there are three groups of antifungal agents, which can be used in the 
therapy of aspergillosis: azoles, polyenes, and echinocandins [99]. The choice of 
treatment regimen depends on several factors, including the host’s immune status, 
liver, and kidney functions, and prior antifungal therapies [99]. Treatment regi-
mens of invasive aspergillosis are shown in Figure 2.
It should be emphasized that in the choice of proper antifungal therapy, suscep-
tibility testing of the cultured isolate is important in view of an emerging resistance 
of some Aspergillus strains to azoles, as well as identification to the species level, as 
resistance to antifungals is more likely with certain species of Aspergillus other than 
Aspergillus fumigatus [99]. For example, A. terreus has a high minimum inhibitory 
concentration (MIC) to amphotericin B, while A. calidoustus has to numerous anti-
fungals [99]. The role of a combination antifungal treatment for primary therapy of 
IA remains controversial; however, it may be considered (e.g. voriconazole with an 
echinocandin) for treatment of infection caused by these species [71, 99].
Apart from antifungal therapy, surgery may be indicated in patients with 
invasive aspergillosis. It applies to the cases in which the disease is localized and 
infection site is easily accessible to debridement (e.g. invasive fungal sinusitis or 
localized cutaneous lesions) [5, 6]. Surgical excision or debridement may be used 
for both diagnostic and therapeutic purposes [44].
Surgery of the sinuses may involve removal of the granulation tissue and 
necrotic bone [3]. Surgery may also be required in patients with endocarditis, osteo-
myelitis, or focal lesions in the central nervous system [5, 6]. Surgery is particularly 
indicated for persistent, or a life-threatening hemoptysis, lesions in the proximity 
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of great vessels or pericardium, nasal and sinus infections, single cavitary lesion in 
the lung, intracranial abscesses, as well as lesions invading the pericardium, bone, 
the subcutaneous, or thoracic tissue [100].
6.1 Triazoles
According to the newest guidelines of ECIL-6 (the European Conference on 
Infections in Leukemia), recommendations of Infectious Diseases Society of 
America (IDSA) and European Society of Clinical Microbiology and Infectious 
Diseases, European Confederation of Medical Mycology, European Respiratory 
Society (ESCMID/ECMM/ERS) as well as expert groups, the drugs of first choice 
in therapy of invasive aspergillosis are triazoles—voriconazole or isavuconazole in 
monotherapy [5, 6, 13, 20, 71].
Isavuconazole is as effective as voriconazole, and in addition, it is characterized 
by a better safety profile, therefore in the newest guidelines, it has been granted AI 
recommendation equally with voriconazole [5, 6]. In patients who do not tolerate 
voriconazole, therapy with itraconazole or posaconazole may be considered; how-
ever, cross-resistance between azoles may be a problem [5]. An alternative antifungal 
agent used in the therapy of this disease is liposomal amphotericin B [5, 6, 13, 71]. It 
is emphasized that the chosen agent should be implemented as quickly as possible 
after fungal etiology of the infection has been suspected [5, 15]. At present, the 
routine use of combination therapy is neither recommended as a first line treatment, 
nor the use of echinocandins as the primary treatment [5].
In recent years, an increase in the percentage of strains of Aspergillus fumigatus 
resistant to azoles (including voriconazole) is being observed, which may pose a 
therapeutic problem [20, 101–103]. Resistance is mainly due to mutations in the 
gene cyp51A and/or overexpression of the efflux pumps in the cells of these fungi 
[101–106]. Lestrade et al. showed that among 196 patients with IA, in 37 (19%) 
infection was caused by a strain of A. fumigatus resistant to voriconazole, which was 
linked to >20% increase in the mortality rate in this group of patients in compari-
son to individuals who received proper antifungal treatment [107]. In 2006–2016, 
Borman et al. analyzed 2501 clinical strains of Aspergillus fumigatus, among which 
Figure 2. 
Treatment of invasive aspergillosis.
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3.1% were resistant to voriconazole and 12.5% were resistant to amphotericin B 
[108]. The range of MIC values for these strains to voriconazole was 0.03–16.0 μg/
ml and to amphotericin B was 0.06–4.0 μg/ml [108]. In a study comprising 105 
clinical strains of Aspergillus fumigatus, a significant difference was reported in the 
percentage of strains resistant to triazoles among the isolates cultured from samples 
obtained from hematological patients (15.9%), in comparison with the group of 
patients treated in the ICU (4.5% strains) [101].
Voriconazole has emerged as the preferred agent for primary therapy of IA. Its effi-
cacy has been confirmed in many studies, including hematopoietic stem cell transplant 
recipients and patients with hematological malignancies, as well as SOT recipients 
[44]. Voriconazole was effective in heart transplant recipients, in SOT recipients with 
central nervous system aspergillosis. In a lung transplant patient with Aspergillus endo-
phthalmitis, voriconazole has been used in the form of an intravitreal injection [44].
6.2 Liposomal amphotericin B
An alternative antifungal agent recommended in therapy of IA is liposomal 
amphotericin B (L-AmB), which is active in vitro against the majority of strains 
of Aspergillus [5, 6, 13, 44, 71, 99]. However, it should be remembered that some 
species of Aspergillus (e.g. A. terreus) neutropaenic patients may be resistant to this 
antifungal agent.
6.3 Echinocandins
Echinocandins (caspofungin, micafungin, or anidulafungin) are not recom-
mended as first-line therapy of invasive aspergillosis, as they exhibit only fungi-
static (not fungicidal) activity against the isolates of Aspergillus spp. They can be 
considered in salvage therapy; however, in combination with voriconazole, isavuco-
nazole, or liposomal amphotericin B [44, 99, 109].
6.4 Salvage therapy
In patients not responding to monotherapy with antifungal agents recom-
mended as first-line therapy, such as voriconazole, isavuconazole, or liposomal 
amphotericin B, a salvage therapy must be considered, with the use of a com-
bination antifungal regimen [99]. In these cases, it is suggested to combine an 
echinocandin (caspofungin, micafungin, or anidulafungin) with voriconazole, 
isavuconazole, or liposomal amphotericin B, while there are no clinical data to 
support the use of triazoles in combination with amphotericin B [99]. Apart from 
salvage antifungal therapy, reduction of the doses of immunosuppressive agents (if 
feasible), as well as surgery should be considered in these patients.
6.5 Duration of antifungal therapy
The duration of therapy for IA is usually 12 weeks, but may range from 3 to 
>50 weeks or may be even lifelong [5, 6, 13, 44]. Many factors may influence it, such 
as the response to administered therapy, the patient’s immune status and underlying 
diseases [44]. It is recommended to continue therapy until all clinical and radiographic 
abnormalities have resolved, and cultures are negative for Aspergillus. In transplant 
recipients, it is important to lower the doses of immunosuppressive agents, as well as 
to monitor an allograft function [44]. Patterson et al. and other expert groups recom-
mend that therapy of invasive pulmonary aspergillosis should be continued for at least 
6–12 weeks, depending on the site of disease, degree and duration of immunosuppres-
sion, and evidence of improvement of the patient’s clinical status [5, 6]. In patients 
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with stable and pharmacokinetically predictable status, physicians should consider 
switching from intravenous to oral therapy [13]. If immunosuppression has to be 
continued after successful therapy of invasive aspergillosis, secondary prophylaxis 
should be initiated to prevent recurrence of the infection [5, 6].
6.6 Prophylaxis of invasive aspergillosis in transplant recipients
Antifungal prophylaxis against aspergillosis should be used in patients at high 
risk of IA during prolonged neutropenia [5, 6]. It is recommended to administer 
posaconazole, voriconazole, or micafungin (caspofungin is also probably effective) 
[5, 6]. Prophylaxis with itraconazole is effective, but absorption and tolerability of 
this drug may be a problem.
For allogeneic HSCT recipients with graft-versus-host disease (GVHD), who are 
at high risk for IA, prophylaxis with posaconazole is recommended, but other azoles 
active against Aspergillus may also be used [5, 6]. In patients with chronic immu-
nosuppression associated with GVHD antifungal prophylaxis should be continued 
throughout the duration of immunosuppression [5, 6].
According to the ECIL-6 and other recommendations, antifungal prophy-
laxis with either a systemic triazole (voriconazole or itraconazole) or an inhaled 
AmB product is recommended for 3–4 months after lung transplantation [5, 6]. 
Aerosolized amphotericin B is an option which allows the direct administration of the 
antifungal agent into the transplanted lung, with avoidance of systemic unwanted 
effects and drug–drug interactions [44]. However, for certain groups of lung trans-
plant recipients (single lung transplant recipients, mold colonization before or after 
lung transplantation, mold infections detected in explanted lungs, and fungal infec-
tions of the sinus) systemic voriconazole or itraconazole is recommended rather than 
inhaled AmB. Patterson et al. and other experts recommend reinitiation of antifungal 
prophylaxis in lung transplant recipients who receive immunosuppression augmenta-
tion with thymoglobulin, alemtuzumab, or high-dose corticosteroids [5, 6].
For other SOT recipients, antifungal prophylaxis against IA is not routinely 
recommended and should be based on the institutional epidemiology of aspergil-
losis and assessment of the patient’s risk factors [5, 6, 44]. A common approach to 
antifungal prophylaxis in liver transplant recipients is to target high-risk patients 
(fulminant hepatic failure, reoperation, retransplantation, or with renal failure), 
and it is administered during pre-transplant hospitalization and for the first-month 
posttransplant. Risk factors for IA have also been identified in heart transplant 
recipients, such as pretransplant colonization with Aspergillus spp., reoperation, 
cytomegalovirus (CMV) infection, and renal dysfunction. Other risk factors for IA, 
which may justify antifungal prophylaxis are institutional outbreaks and prolonged 
or high-dose corticosteroid therapy; however, the optimal duration of such prophy-
laxis has not been determined [5, 6].
6.7 Immunomodulatory agents and new therapeutic options
At present, it is recommended to reduce the doses of immunosuppressive 
therapy administered to the patient (or eliminate it, if possible), as this improves 
the outcome of anti-Aspergillus therapy [5, 6]. Other approaches can be considered 
in cases not responding to standard antifungal therapy, such as granulocyte transfu-
sions in neutropenic patients with IA, or recombinant interferon-γ as prophylaxis in 
patients with chronic granulomatous disease (CGD) [5, 6].
A relatively new approach to the therapy of invasive aspergillosis in immuno-
compromised patients involves the use of immunomodulatory agents which would 
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selected cytokines or colony-stimulating factors (e.g. granulocyte colony-stimulat-
ing factor, G-CSF; granulocyte-macrophage colony-stimulating factor, GM-CSF; 
interferon-γ) with immunomodulatory effect [44, 110].
There is an ongoing search for new, more effective antifungals, which will be 
active also against drug-resistant isolates of Aspergillus spp. Currently, there are 
new classes of antifungal drugs under development—two agents in phase 2 study 
for the therapy of systemic invasive fungal infections and one drug in phase 1 [111]. 
Among them are agents which show activity against resistant to azoles cyp51A 
mutants of Aspergillus spp.
7. Summary
Diagnosis of invasive aspergillosis remains a challenge for clinicians and microbi-
ologists. Progress in modern diagnostic methods and imaging techniques may con-
tribute to an early and reliable diagnosis of infections caused by Aspergillus spp. This 
is particularly important in immunocompromised patients, such as HSCT and SOT 
recipients. Proper choice and early commencement of antifungal therapy increase 
the chances for survival and recovery of these patients from invasive aspergillosis.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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